Zum Inhalt springen

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research (“AACR”) Annual Meeting, taking place in San Diego, California from April 5-10, 2024. Among the data presented will be updated immunogenicity data from the ongoing Phase 1 (AMPLIFY-201) study of ELI-002, an off-the-shelf investigational therapeutic cancer vaccine for patients with mutant Kirsten rat sarcoma (“mKRAS”)-driven pancreatic and colorectal cancers. Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared. Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase… 

more »Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on April 1, 2024, to six newly-hired, non-executive employees. The inducement grants were approved by the Company’s independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on April 1, 2024 (the “Grant Date”), ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024. ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Precision Biologics to Present at AACR

Precision Biologics, Inc. reports its lead monoclonal antibody, NEO-201, targets circulating human naïve regulatory T cells (Tregs) in both healthy donors and cancer patients. A poster presentation discussing this data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024. Poster title: The O-glycan epitope targeting anti-human carcinoma monoclonal antibody (mAb) NEO-201 can also target human regulatory T cells (Tregs) . This study was performed by Drs. Atsushi Tanaka and Shimon Sakaguchi from Osaka University, Japan. Dr. Sakaguchi’s group independently analyzed by flow cytometry the ability of NEO-201 to recognize naïve Tregs in peripheral blood mononuclear cells (PBMCs) from healthy donors, confirming findings from Precision Biologics in PBMCs from cancer patients. In this study, human PBMCs were collected from 7 healthy donors (HD) at Osaka University and 6 cancer patients from Precision Biologics ongoing phase II… 

more »Precision Biologics to Present at AACR

Clarius and ThinkSono Introduce a New AI-Guided Ultrasound System Enabling Rapid Assessments of DVTs

Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and ThinkSono, a pioneering medical technology company specializing in ultrasound artificial intelligence (AI) guidance solutions, are introducing a new AI-guided ultrasound system in Europe, which will improve the efficiency of detecting deep vein thrombosis (DVT). ThinkSono Guidance, an AI App that pairs with Clarius ultrasound scanners, recently attained Class llb CE mark regulatory approval. DVT is a blood clot found commonly in the leg and is a leading cause of preventable hospital death in Europe and the United States. Patients often wait for hours or days for test results performed by ultrasound-trained clinicians.

Brain cancer community gets help in accessing clinical trials

myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive. Under the new partnership, people with brain tumors will be equipped with the means to bolster their knowledge of relevant treatment options, potentially extending to participation in clinical trials and access to pre-approval drugs. Moreover, the partnership provides a new layer of support to clinicians in their efforts to recruit patients to relevant clinical trials. There are 80,000 people living with a brain tumor in England alone, with a patient receiving a diagnosis every two hours. Brain tumors kill more children and adults under the age of 40 than any other cancer, and incidences and deaths from brain tumors are on the rise. With… 

more »Brain cancer community gets help in accessing clinical trials

Diana Stolz: Apotheken sind Teil der medizinischen Versorgung

Hessens Gesundheitsministerin Diana Stolz hat beim Auftaktgespräch mit der Landesapothekerkammer auf die Bedeutung der Apotheken als Teil der medizinischen Versorgung hingewiesen. „Die Apotheken sind Teil der Gesundheitsversorgung der Menschen in Hessen. Sie haben – wie die Kliniken oder Niedergelassenen – mit dem Fachkräftemangel und Nachwuchsproblemen zu kämpfen. Wir werden die hier anstehenden Herausforderungen gemeinsam anpacken. […] Diana Stolz: Apotheken sind Teil der medizinischen Versorgung

Weltweit werden sich die Fälle von Prostatakrebs in 20 Jahren verdoppeln

Eine Studie in „The Lancet“ warnt davor, dass die jährlichen Fälle von Prostatakrebs von 1,4 Millionen im Jahr 2020 auf 2,9 Millionen im Jahr 2040 ansteigen werden und dass die Zahl der Todesfälle um fast 85 % zunehmen wird 700.000 im gleichen Zeitraum, hauptsächlich unter Männern in Ländern mit niedrigem und mittlerem Einkommen. Aufgrund der… Weltweit werden sich die Fälle von Prostatakrebs in 20 Jahren verdoppeln